Zobrazeno 101 - 110
of 150
pro vyhledávání: '"Onyee Chan"'
Autor:
Nathan P. Horvat, Rami Komrokji, Najla Al Ali, Chetasi Talati, Eric Padron, David Sallman, Kendra Sweet, Onyee Chan, Jeffrey Lancet, Andrew T. Kuykendall
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S232
Autor:
Rami S. Komrokji, David A. Sallman, Kendra Sweet, Najla Al Ali, Andrew T. Kuykendall, Onyee Chan, Jeffrey E. Lancet, Eric Padron
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S341
Context: Azacitidine (aza) remains the backbone of treating higher-risk MDS patients (pts), with less than 20% of pts achieving complete response (CR) and median overall survival of 14–18 months. Ongoing studies in higher-risk MDS are assessing the
Autor:
Onyee Chan, Najla Al Ali, Seongseok Yun, Chetasi Talati, Andrew Kuykendall, Eric Padron, David Sallman, Kendra Sweet, Rami Komrokji, Jeffrey Lancet
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S214
Autor:
Sokolova, Alexandra1, Onyee Chan2 onyeec@deptofmed.arizona.edu, Ullah, Waqas2, Hamdani, Auon Abbas2, Anwer, Faiz2,3, Chan, Onyee4 (AUTHOR)
Publikováno v:
Journal of Medical Case Reports. 4/11/2017, Vol. 11, p1-5. 5p.
Publikováno v:
Blood. 136:31-32
Background: Therapy related myelodysplastic syndromes (t-MDS) account for 10-20% of all myelodysplastic syndromes (MDS). They are associated with poor outcome namely driven by high occurrence of poor risk cytogenetics and TP53 mutations. Acquired SF3
Publikováno v:
Blood. 136:25-26
Background: Genetic alterations are increasingly being recognized to play an important role in both diagnosis and prognosis of MDS. In general, SF3B1 mutated MDS is known to have favorable outcomes whereas those with mutated TP53 have dismal survival
Autor:
Kendra Sweet, Gregoire Calon, David A. Sallman, Rami S. Komrokji, Onyee Chan, Ling Zhang, Virginia O. Volpe, Andrew T. Kuykendall, Constantine Logothetis, Eric Padron, Nathan P. Horvat, Seongseok Yun, Chetasi Talati, Nicole D. Vincelette, Jeffrey E. Lancet
Publikováno v:
Journal of Clinical Oncology. 39:e19010-e19010
e19010 Background: Recent studies showed that IDH1/2 are frequently mutated in AML and that aberrant 2-HG elevation driven by the mutant IDH1/2 proteins plays a pivotal role in AML development. Subsequent clinical trials of IDH1/2 inhibitors demonstr
Autor:
Rami S. Komrokji, Chirag K Bhagat, Yehuda E. Deutsch, Terrence Bradley, Chetasi Talati, Onyee Chan, Somedeb Ball, Wassim Samra, Todd C. Knepper, Jeffrey E. Lancet, Eric Padron, Justin M. Watts, David A. Sallman, Kendra Sweet, Mohammad Hussaini
Publikováno v:
Journal of Clinical Oncology. 39:7024-7024
7024 Background: Extramedullary (EM) involvement, including myeloid sarcoma (MS) and leukemia cutis (LC), is uncommon in patients with acute myeloid leukemia (AML). Mutational landscape of EM-AML is not well characterized, including concordance of se
Autor:
Anca Georgescu, Onyemaechi Okolo, Volodymyr Shponka, Aneela Majeed, Daniel O. Persky, Onyee Chan
Publikováno v:
Case Reports in Oncology, Vol 10, Iss 2, Pp 542-547 (2017)
Case Reports in Oncology
Case Reports in Oncology
Hodgkin lymphoma with symptomatic osseous involvement can have a similar presentation to osteomyelitis. Common findings in symptoms, laboratory workup, and imaging can make it very difficult to distinguish between the two diseases. Excisional biopsy
Autor:
Akshay Amaraneni, Irbaz Bin Riaz, Muhammad Husnain, Faiz Anwer, Ali McBride, Onyee Chan, Faisal Akbar, Umar Zahid, Ahmad Iftikhar
Publikováno v:
Current Hematologic Malignancy Reports. 12:217-226
Chemotherapy remains the first-line therapy for aggressive lymphomas. However, 20–30% of patients with non-Hodgkin lymphoma (NHL) and 15% with Hodgkin lymphoma (HL) recur after initial therapy. We want to explore the role of high-dose chemotherapy